A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease.

Trial Profile

A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs MEDI 1814 (Primary) ; MEDI 1814 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 20 Jul 2017 Results (n=77) presented at the Alzheimer's Association International Conference 2017
    • 10 Jun 2017 Biomarkers information updated
    • 26 Sep 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top